MarkJHamblinMD
Pulmonology • Kansas City, KSCritical Care Medicine, Interstitial Lung Diseases, Pleural Disease, Restrictive Lung Disease
Assistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Hamblin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
# Stop
Kansas City, KS 66160Phone+1 913-588-6046Fax+1 913-588-4098
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Tulane UniversityResidency, Internal Medicine, 2003 - 2007
University of Missouri-Columbia School of MedicineClass of 2003
Certifications & Licensure
MO State Medical License 2021 - 2026
KS State Medical License 2011 - 2025
LA State Medical License 2004 - 2008
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Roles: Contact
- Platform Clinical Study for Conquering Scleroderma Start of enrollment: 2024 Apr 15
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsHypersensitivity Pneumonitis: Updates in Evaluation, Management, and Ongoing Dilemmas.Sahil M Pandya, Aarti P Pandya, Daffolyn Rachael Fels Elliott, Mark J Hamblin
Immunology and Allergy Clinics of North America. 2023-05-01 - 20 citationsA Phase IIb Randomized Clinical Study of an Anti-αβMonoclonal Antibody in Idiopathic Pulmonary Fibrosis.Ganesh Raghu, Majd Mouded, Daniel C Chambers, Fernando J Martinez, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine. 2022-11-01 - 19 citationsLong-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extensio...Ganesh Raghu, Mark J Hamblin, A Whitney Brown, Jeffrey A Golden, Lawrence A Ho
Respiratory Research. 2022-05-21
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
